Corline Q2 results after financial items narrow to SEK -1.44 million; net sales rise 114.28% to SEK 4.69 million vs year-ago quarter

Reuters2026/08/26 06:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Corline Biomedical net sales more than doubled to SEK 8.98 million in January–June 2026.
Loss after financial items narrowed to SEK 3.94 million, with EPS at about SEK -0.15.
Second-quarter net sales climbed 114.27% to SEK 4.69 million, while the loss after financial items narrowed to SEK 1.44 million.
Cash totaled SEK 33 million at June 30, with equity ratio at 87%.
CEO Henrik Nittmar said first-half sales already exceed full-year 2025, while Kardium’s Globe catheter rollout remains in an early expansion phase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corline Biomedical AB published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260235OMX_____CNEWS_SV_GNW1001259372_sv) on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Corline Q2 results after financial items narrow to SEK -1.44 million; net sales rise 114.28% to SEK 4.69 million vs year-ago quarter

You may also like

Crypto prices